KBY Biotech Indexv0.0.34
Search
← Pipeline|Fixamavacamten

Fixamavacamten

Phase 2
DVA-2301
By Dynavax
Source: Trial-derived·Trials: 2
Modality
Multispecific
MOA
JAK1/2i
Target
SOS1
Pathway
Complement
AMLEwing SarcomaLGS
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
~Sep 2018
→ ~Dec 2019
Phase 2
Mar 2020
→ Apr 2030
Phase 2Current
NCT06250055
943 pts·LGS
2020-03→TBD·Completed
NCT05321304
1,365 pts·Ewing Sarcoma
2025-09→2030-04·Completed
2,308 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-074.0y awayPh2 Data· Ewing Sarcoma
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Complet…
P2
Complet…
Catalysts
Ph2 Data
2030-04-07 · 4.0y away
Ewing Sarcoma
Completed|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT06250055Phase 2LGSCompleted943UPCR
NCT05321304Phase 2Ewing SarcomaCompleted1365Safety
Competitors (10)
DrugCompanyPhaseTargetMOA
FixanesiranAbbViePreclinicalRETJAK1/2i
TerarelsinAbbViePreclinicalSOS1SOS1i
RibofutibatinibAstraZenecaPhase 2/3SOS1PCSK9i
MotavorutinibAmgenPhase 3CDK4/6JAK1/2i
VoxacageneGilead SciencesPhase 2/3SOS1TYK2i
VRT-9481Vertex PharmaPhase 1/2MeninJAK1/2i
SovarelsinBioMarinPhase 2CFTRJAK1/2i
SRP-9822SareptaPhase 3SOS1FGFRi
PeminaritideSareptaNDA/BLAPLK4JAK1/2i
NiramavacamtenHansoh PharmaPhase 2SGLT2JAK1/2i